All In Biotech

Drug Trial Radar · NCT02571777

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

Last checked: Nov 19, 2026Latest source record: Jul 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,092 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,092

Actual

Start

Dec 8, 2015

Primary completion

Jun 14, 2019

Study completion Jun 14, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320) μg via Concept1 in poorly controlled asthmatics as determined by pulmonary function testing and effects on asthma control.

Conditions

  • Asthma

Interventions

  • QVM149 150/50/160Drug

  • QVM149 150/50/80Drug

  • QMF149 150/320Drug

  • QMF149 150/160Drug

  • salmeterol/fluticasoneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26Time frame: 26 weeks

Locations

403 sites in 41 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Mendoza, Argentina

  • Novartis Investigative Site

    Mendoza, Argentina

  • Novartis Investigative Site

    Paraná, Argentina

  • Novartis Investigative Site

    Santa Fe, Argentina

  • Novartis Investigative Site

    Santa Fe, Argentina

  • Novartis Investigative Site

    Bahía Blanca, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Florida, Buenos Aires, Argentina

  • Novartis Investigative Site

    Lanus, Buenos Aires, Argentina

  • Novartis Investigative Site

    Mar del Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Mar del Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Nueve de Julio, Buenos Aires, Argentina

  • Novartis Investigative Site

    San Nicolás de los Arroyos, Buenos Aires, Argentina

  • Novartis Investigative Site

    Vicente López, Buenos Aires, Argentina

  • Novartis Investigative Site

    Villa María, Córdoba Province, Argentina

  • Novartis Investigative Site

    Concepción del Uruguay, Entre Ríos Province, Argentina

  • Novartis Investigative Site

    Godoy Cruz, Mendoza Province, Argentina

  • Novartis Investigative Site

    Santa Fe, Rosario, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Novartis Investigative Site

    Bludenz, Austria

  • Novartis Investigative Site

    Feldbach, Austria

  • Novartis Investigative Site

    Feldkirch, Austria

  • Novartis Investigative Site

    Grieskirchen, Austria

  • Novartis Investigative Site

    Braine L Alleud Waterloo, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Éghezée, Belgium

Showing 40 of 403 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.